NEW TESTING PROCEDURE HOLDS PROMISE AS A CRITICAL TOOL IN THE GLOBAL EFFORT TO ELIMINATE MALARIA

Field laboratory-deployable molecular test up to 80,000 times more sensitive than current options

CINCINNATI, April 25 (Bernama-GLOBE NEWSWIRE) -- As the global community gathers for World Malaria Day to celebrate successes and plot strategy to eliminate the disease from the face of the earth, a new ray of hope is emerging from a surprising place: the testing side of the equation.

Meridian Bioscience, Inc. of Cincinnati, Ohio (NASDAQ:VIVO) has developed illumigene® Malaria, a molecular-based, field laboratory-deployed test for malaria that is up to 80,000 times more sensitive at detecting the malaria parasite than current testing options. The test was developed by Meridian with the technical assistance of the Centers for Disease Control and Prevention (CDC) and Cheikh Anta Diop University of Dakar, Senegal.

http://mrem.bernama.com/viewsm.php?idm=28961